Adverum: Interim Gene Therapy Data in Macular Degeneration Phase 1 Trial

— Robust efficacy with evidence of a dose response —
— 6/6 patients rescue-injection-free in cohort 1, with 3 patients at 52 weeks —
— 4/6 patients rescue-injection-free in cohort 2 (lower dose) at 24 weeks —

— Company to host and webcast a discussion with key opinion leaders Sunday, February 9, at 10:00 am EST —

 Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced new interim clinical data from the OPTIC Phase 1 dose-ranging clinical trial of ADVM-022 intravitreal injection gene therapy. OPTIC includes treatment-experienced patients with wet age-related macular degeneration (AMD). The data are being presented today by David S. Boyer, M.D., senior partner, Retina-Vitreous Associates Medical Group and adjunct clinical professor of ophthalmology with the University of Southern California/Keck School of Medicine in Los Angeles, at the Angiogenesis, Exudation, and Degeneration 2020 Annual Meeting in Miami.
A copy of the presentation is available on the Adverum corporate website under Events and Presentations in the Investors section.
https://www.marketscreener.com/ADVERUM-BIOTECHNOLOGIES-27535811/news/Adverum-Biotechnologies-Reports-New-Interim-Data-from-Cohorts-1-and-2-of-OPTIC-Phase-1-Trial-of-ADVM-29967519/